Pfizer anticipates developing eight or more potential "blockbuster" cancer drugs by 2030.
Pfizer anticipates the new drugs will contribute approximately 65% of its oncology revenues and also said it hopes to double the number of patients treated with its new cancer medication from about 2.3 million in 2023, it said in a company news release.
"With the completion of the Seagen acquisition in 2023, Pfizer has significantly expanded its oncology organization to amplify its efforts to advance new standards of care and improve outcomes for patients," Chris Boshoff, MD, PhD, chief oncology officer and executive vice president at Pfizer, said in the release.
The company plans to focus on four main cancer types — breast, genitourinary, thoracic and blood. The company already has products in these types, but said it foresees many of the current drugs falling out of circulation and being replaced with new medications.